|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
3
|
Charafe-Jauffret E, Ginestier C, Iovino F,
Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F,
Dutcher J, et al: Breast cancer cell lines contain functional
cancer stem cells with metastatic capacity and a distinct molecular
signature. Cancer Res. 69:1302–1313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lapidot T, Sirard C, Vormoor J, Murdoch B,
Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and
Dick JE: A cell initiating human acute myeloid leukaemia after
transplantation into SCID mice. Nature. 367:645–648. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar
|
|
6
|
Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai
P, Chu PW, Lam CT, Poon RT and Fan ST: Significance of
CD90+ cancer stem cells in human liver cancer. Cancer
Cell. 13:153–166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vermeulen L, Sprick MR, Kemper K, Stassi G
and Medema JP: Cancer stem cells - old concepts, new insights. Cell
Death Differ. 15:947–958. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Beck B and Blanpain C: Unravelling cancer
stem cell potential. Nat Rev Cancer. 13:727–738. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Medema JP: Cancer stem cells: The
challenges ahead. Nat Cell Biol. 15:338–344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takebe N, Harris PJ, Warren RQ and Ivy SP:
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog
pathways. Nat Rev Clin oncol. 8:97–106. 2011. View Article : Google Scholar
|
|
11
|
Hoey T, Yen WC, Axelrod F, Basi J,
Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A, et
al: DLL4 blockade inhibits tumor growth and reduces
tumor-initiating cell frequency. Cell Stem Cell. 5:168–177. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okamoto OK and Perez JF: Targeting cancer
stem cells with monoclonal antibodies: A new perspective in cancer
therapy and diagnosis. Expert Rev Mol Diagn. 8:387–393. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sharma BK, Manglik V, O'Connell M,
Weeraratna A, McCarron EC, Broussard JN, Divito KA,
Simbulan-Rosenthal CM, Rosenthal DS and Zapas JL: Clonal dominance
of CD133+ subset population as risk factor in tumor
progression and disease recurrence of human cutaneous melanoma. Int
J Oncol. 41:1570–1576. 2012.PubMed/NCBI
|
|
14
|
Wright MH, Calcagno AM, Salcido CD,
Carlson MD, Ambudkar SV and Varticovski L: Brca1 breast tumors
contain distinct CD44+/CD24− and
CD133+ cells with cancer stem cell characteristics.
Breast Cancer Res. 10:R102008. View
Article : Google Scholar
|
|
15
|
Hermann PC, Huber SL, Herrler T, Aicher A,
Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations
of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007.
View Article : Google Scholar
|
|
16
|
Eramo A, Lotti F, Sette G, Pilozzi E,
Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De
Maria R: Identification and expansion of the tumorigenic lung
cancer stem cell population. Cell Death Differ. 15:504–514. 2008.
View Article : Google Scholar
|
|
17
|
Scott AM, Allison JP and Wolchok JD:
Monoclonal antibodies in cancer therapy. Cancer Immun.
12:142012.PubMed/NCBI
|
|
18
|
Coulson A, Levy A and Gossell-Williams M:
Monoclonal antibodies in cancer therapy: Mechanisms, successes and
limitations. West Indian Med J. 63:650–654. 2014.
|
|
19
|
Davis TA, Grillo-López AJ, White CA,
McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL,
Rosenberg J and Levy R: Rituximab anti-CD20 monoclonal antibody
therapy in non-Hodgkin's lymphoma: Safety and efficacy of
re-treatment. J Clin oncol. 18:3135–3143. 2000.PubMed/NCBI
|
|
20
|
Köhler G and Milstein C: Continuous
cultures of fused cells secreting antibody of predefined
specificity. Nature. 256:495–497. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boyiadzis M and Foon KA: Approved
monoclonal antibodies for cancer therapy. Expert Opin Biol Ther.
8:1151–1158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang C, Xiong F, Wang J, Dou J, Chen J,
Chen D, Zhang Y, Luo S and Gu N: Anti-ABCG2 monoclonal antibody in
combination with paclitaxel nanoparticles against cancer stem-like
cell activity in multiple myeloma. Nanomedicine (Lond). 9:45–60.
2014. View Article : Google Scholar
|
|
23
|
Morris MJ, Eisenberger MA, Pili R,
Denmeade SR, Rathkopf D, Slovin SF, Farrelly J, Chudow JJ, Vincent
M, Scher HI, et al: A phase I/IIA study of AGS-PSCA for
castration-resistant prostate cancer. Ann Oncol. 23:2714–2719.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sharkey RM, Hajjar G, Yeldell D, Brenner
A, Burton J, Rubin A and Goldenberg DM: A phase I trial combining
high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with
doxorubicin and peripheral blood stem cell rescue in advanced
medullary thyroid cancer. J Nucl Med. 46:620–633. 2005.PubMed/NCBI
|
|
25
|
Liu H, Zhang W, Jia Y, Yu Q, Grau GE, Peng
L, Ran Y, Yang Z, Deng H and Lou J: Single-cell clones of liver
cancer stem cells have the potential of differentiating into
different types of tumor cells. Cell Death Dis. 4:e8572013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun L, Chen L, Sun L, Pan J, Yu L, Han L,
Yang Z, Luo Y and Ran Y: Functional screen for secreted proteins by
monoclonal antibody library and identification of Mac-2 Binding
protein (Mac-2BP) as a potential therapeutic target and biomarker
for lung cancer. Mol Cell Proteomics. 12:395–406. 2013. View Article : Google Scholar :
|
|
27
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pang R, Law WL, Chu AC, Poon JT, Lam CS,
Chow AK, Ng L, Cheung LW, Lan XR, Lan HY, et al: A subpopulation of
CD26+ cancer stem cells with metastatic capacity in
human colorectal cancer. Cell Stem Cell. 6:603–615. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fan F, Samuel S, Evans KW, Lu J, Xia L,
Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA, et al: overexpression of
snail induces epithelial-mesenchymal transition and a cancer stem
cell-like phenotype in human colorectal cancer cells. Cancer Med.
1:5–16. 2012. View
Article : Google Scholar
|
|
30
|
Ho MM, Ng AV, Lam S and Hung JY: Side
population in human lung cancer cell lines and tumors is enriched
with stem-like cancer cells. Cancer Res. 67:4827–4833. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Leung EL, Fiscus RR, Tung JW, Tin VP,
Cheng LC, Sihoe AD, Fink LM, Ma Y and Wong MP: Non-small cell lung
cancer cells expressing CD44 are enriched for stem cell-like
properties. PLoS One. 5:e140622010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liang D and Shi Y: Aldehyde
dehydrogenase-1 is a specific marker for stem cells in human lung
adenocarcinoma. Med Oncol. 29:633–639. 2012. View Article : Google Scholar
|
